This report provides a preview of clinical trials that are planned to be initiated and projected to be completed in 2023.
Scope
- The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database. The data included planned clinical trials with a start date from January 1 to December 31, 2023, captured in the database as of December 15, 2022. The planned trials were analyzed and segmented by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use. Clinical trials with an ongoing or planned status with an end date between January 1 and December 31, 2023, were also examined. The trials that are estimated to be completed in 2023 were split by phase, status, indication, sponsor type, top sponsors, geography and DCT use. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
Reasons to Buy
- Understand the planned trials landscape and trends for 2023
- Provide early insight for studies expected to be completed in 2023
- The 2023 trends of DCTs in both planned trials and trials to be completed
Table of Contents
- Executive Summary
- Introduction
- Clinical Trials Planned to Initiate in 2023
- Clinical Trials Estimated to Complete in 2023
- Key Findings
- Appendix
Figures 1 and 2: Planned Clinical Trials, by Phase and Sponsor Type
Figure 3: Planned Clinical Trials Top Industry Sponsors, by Phase
Figure 4: Planned Clinical Trials Top Non-Industry Sponsors, by Phase
Figure 5: Planned Clinical Trials Single Country or Multinational, by Sponsor Type and Phase
Figure 6: Planned Clinical Trials Regions, by Phase
Figure 7: Planned Clinical Trials Regions, by Phase and Distribution
Figure 8: Planned Clinical Trials Country, by Phase
Figure 9: Planned Clinical Trials Country, by Phase and Distribution
Figures 10 and 11: Planned Clinical Trials Primary Intervention Molecule Type, by Phase and Distribution
Figure 12: Planned Clinical Trials Top Therapy Areas, by Phase
Figure 13: Planned Clinical Trials Top Therapy Areas, by Phase and Distribution
Figure 14: Planned Clinical Trials Top Indications, by Phase
Figure 15: Planned Clinical Trials Top Indications, by Phase and Distribution
Figures 16 and 17: Total Planned Clinical DCT Trials, by Therapeutic Area
Figure 18: Estimated to Complete Clinical Trials, by Phase
Figures 19 and 20: Estimated to Complete Clinical Trials by Status, by Phase and Phase Distribution
Figure 21: Estimated to Complete Clinical Trials, by Sponsor Type and Phase
Figure 22: Estimated to Complete Clinical Trials, by Top Industry Sponsor and Phase
Figure 23: Estimated to Complete Clinical Trials, by Top Non-Industry Sponsor and Phase
Figure 24: Estimated to Complete Single Country or Multinational Clinical Trials, by Region
Figure 25: Estimated to Complete Clinical Trials, by Country
Figure 26: Estimated to Complete Clinical Trials, by Therapy Area and Phase
Figure 27: Estimated to Complete Clinical Trials, by Indication and Phase
Figures 28 and 29: Total Estimated to Complete DCT Clinical Trials, by Region and Single Country or Multinational
Figure 30: Estimated to Complete DCT Clinical Trials, by Therapy Area and Phase
